12/23
04:21 pm
dnli
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions [Yahoo! Finance]
Low
Report
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions [Yahoo! Finance]
12/23
03:17 pm
dnli
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? [Yahoo! Finance]
Low
Report
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? [Yahoo! Finance]
12/23
05:31 am
dnli
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks [Yahoo! Finance]
Medium
Report
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks [Yahoo! Finance]
12/11
09:50 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its price target lowered by analysts at Wedbush from $31.00 to $30.00. They now have an "outperform" rating on the stock.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its price target lowered by analysts at Wedbush from $31.00 to $30.00. They now have an "outperform" rating on the stock.
12/10
01:01 am
dnli
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
12/10
12:14 am
dnli
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
12/9
04:37 pm
dnli
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
12/9
04:01 pm
dnli
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
12/7
12:34 am
dnli
Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound [Yahoo! Finance]
Low
Report
Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound [Yahoo! Finance]
12/6
09:21 pm
dnli
Denali's Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) [Yahoo! Finance]
Low
Report
Denali's Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) [Yahoo! Finance]
12/5
08:09 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
12/5
08:08 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its "outperform" rating reaffirmed by analysts at Wedbush.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its "outperform" rating reaffirmed by analysts at Wedbush.
12/4
07:00 am
dnli
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
Medium
Report
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
11/17
12:08 pm
dnli
Denali Therapeutics (NASDAQ:DNLI) was given a new $37.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) was given a new $37.00 price target on by analysts at Stifel Nicolaus.
11/6
07:03 pm
dnli
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights [Yahoo! Finance]
Low
Report
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights [Yahoo! Finance]
11/6
04:11 pm
dnli
Denali Therapeutics Announces Board and Executive Leadership Updates [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces Board and Executive Leadership Updates [Yahoo! Finance]
11/6
04:01 pm
dnli
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
11/6
04:00 pm
dnli
Denali Therapeutics Announces Board and Executive Leadership Updates
Medium
Report
Denali Therapeutics Announces Board and Executive Leadership Updates
11/4
10:28 am
dnli
Denali Therapeutics (NASDAQ:DNLI) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $26.00. They now have an "overweight" rating on the stock.
Low
Report
Denali Therapeutics (NASDAQ:DNLI) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $26.00. They now have an "overweight" rating on the stock.
10/13
04:21 pm
dnli
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) [Yahoo! Finance]
Low
Report
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) [Yahoo! Finance]
10/13
04:01 pm
dnli
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Low
Report
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)